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development. Here, we review the host genetic studies concerning human leucocyte antigens, antibody receptors,
immune/inflammatory mediators, attachment molecules, cytokines and other factors exerting an immunoregulatory
effect as well as the current genome-wide association studies. We also discuss some viewpoints on future challenges
related to the design of safe and effective prevention and treatment options.
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1. INTRODUCTION
Increasing evidence for the major role of host genetics
has accumulated in research on inter-individual variation in
susceptibility to infectious diseases, particularly since a
HLA allele was found to be susceptible to leprosy (1980)
from early case-control studies of unrelated individuals
with disease and unaffected controls. Host genetic studies
on infectious diseases have identified a number of novel
gene associations that implied the molecular pathways in-
volved in disease pathogenesis [1].
Over the last decade since the completion of the human
genome project, host genetic studies have robustly pro-
gressed using single nucleotide polymorphism (SNP) anal-
ysis, DNA sequencing, DNA microarrays, and cytogenetic
methods. Recently, the technological development of high
throughput genotyping has provided a powerful tool to
examine the genetic basis of disease through Genome-Wide
Association Studies (GWASs). This approach has consider-
ably increased the number of known genes associated with
major diseases [2].
Dengue infections (DI) are a serious cause of morbidity
and mortality in tropical and subtropical areas of the world
including Southeast and South Asia, Central and South
America, and the Caribbean [3]. The disease is caused by
dengue virus (DV), a flavivirus transmitted to humans
mainly by infected Aedes aegypti mosquitoes [4]. Infection
by any of the 4 serotypes of DV, DV-1, -2, -3, and -4, may
result in a wide clinical spectrum, ranging from asympto-
matic to fever (DF), haemorrhagic fever (DHF) and shock
syndrome (DSS), the life threatening complications being
characterized mainly by plasma leakage. Recently, WHO
suggested a new classification which separates severe dengue
patients from those with non-severe dengue [5]. To be
consistent with the publications reviewed, we use WHO
1997 criteria in this paper.
The postulated factors excerting an influence on mani-
festations can be divided into viral and host factors.
Viral factors: Higher blood viral load was detected in
DHF patients in comparison to DF patients [6]. DV-2 had a
larger pleural effusion index than the other virus serotypes
in Thailand [6] and clearly related to the severe clinical
forms in a study in Vietnam [7]. Imported to America, this
genotype is thought to be the cause of the appearance of
DHF in this region [8], providing additional proof for the
higher virulence of the Asian DV-2 genotype.
Host factors: Plasma leakage happens often occurs at
day 4–6 of fever when the viremia has already declined [9],
revealing the role of host immunopathological mechanisms
in disease severity. Both dengue-virus-infected monocytes
with Antibody-Dependent Enhancement (ADE) phenomenon
[10], and activated specific T lymphocytes are responsible
for the rapidly increased levels of cytokines in DHF [11, 12].
These cytokines, especially TNF-α, IFN-γ, and chemical
mediators, including IL-1 and IL-6 from mast cell [13], play
a key role in inducing important clinical manifestations of
DHF, that is, plasma leakage and shock. However, how the
virus-host interaction causes the clinical outcome remains
an important question. Epidemiological evidence indicates
that host genetic factors are relevant and predispose the
DHF/DSS development.
In this review, we summarize the findings from host
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genetic polymorphism studies concerning human leucocyte
antigens, antibody receptors, immune/inflammatory media-
tors, attachment molecule, cytokines and other factors
excerting immunoregulatory effects, as well as the current
status of genome-wide association studies. The accumu-
lated evidences, integrated properly, will provide important
insights into the pathogenesis of severe dengue and shed
light on new prevention and treatment options.
2. HOST GENETIC FACTORS INVOLVED IN THE 
CLINICAL COURSE OF DENGUE VIRUS INFECTION
2.1 The major histocompatibility complex (MHC)
a. Human leucocyte antigen (HLA) –class I and class II sub
regions
HLA is encoded by the major histocompatibility
complex (MHC), located on the chromosome 6 in humans.
The genes encoding HLA class I (HLA-A, -B, -C) and class
II (HLA-DR, DQ and DP) are the most polymorphic in the
human genome [14]. Both class I and II molecules are
involved in displaying peptide antigen to host T lympho-
cytes [15], being the essential recognition elements of
acquired and innate immune responses to viruses [16].
However, the interaction between antigenic epitopes and the
host immune system varies with the HLA allele involved
[17]. Polymorphisms in HLA alleles may correlate with
differential T cell profiles that lead to variable anti-viral
responses [18]. The host HLA allele profile influenced the
reactivity of DV-specific T cells [19] and may be responsi-
ble for the immunopathology of DV infection [20]. This is
why HLA is the most extensively studied allele regarding
the association with severity of DV infection.
Both HLA classes I and II genes were intensively
analyzed (Table 1A, 1B). As in many genetic studies, the
case-control study of HLA association to dengue infection
often compares HLA allele frequencies in DF, DHF/DSS
patients (each form or combined) with those in healthy
controls of the same ethnicity, or by level of disease severity
(DHF/DSS vs. DF or controls). A new trend consistent with
2009 WHO criteria can be seen in studies that separate the
most severe form, DSS and DHF/DF [7, 21, 22, 23], or even
asymptomatic cases [22, 24].
With certain HLA alleles, DV serotype could affect the
clinical outcome, especially DV-2 in Southeast Asia (SEA),
as in the case of B*52 allele associated with secondary DF
only in DV-2 in the Thai population [25], or DRB1*0901
which particularly protects the development to DSS from
DHF in the Kinh ethnic with DV-2 infection [7].
As shown in Table 1, many HLA class I alleles have
been shown to be associated with severe dengue in second-
ary DI, suggesting the importance of the existing primed
memory HLA class I-restricted cross-reactive T cell. This is
not always the case, however, as in A*24 association with
primary infections in a Vietnamese study [7]. Meanwhile,
HLA class II, especially DRB1 alleles, more likely exerted
a protective effect on DI [7, 26, 27] and disease severity
[26]. A better understanding of this protection mechanism
may lead to novel preventive and immuno-therapeutic
approaches, including vaccines.
b. HLA-class III sub-region
Located in the central or class III sub-region of MHC
region [28, 29], tumor necrosis factor (TNF), an important
vasoactive immuno-modulators produced by activated
monocytes, is known to be up-regulated in DHF infections
[30]. As shown in Table 1C, polymorphism in the promoter
region of the TNF-α gene, -308A allele was identified as a
risk for the development of DHF in South American
patients [23, 31] but not in Southeast Asian patients, despite
the much larger sample size of the latter [32, 33]. This SNP
was reported to be important in diabetes mellitus, asthma,
and allergic rhinitis [34], most being associated with DHF
[35]. Another SNP in TNF-α promoter gene, TNF-α-238A,
was found to have no significant association in Vietnamese
[32] but to be significantly increased in secondary DHF
Thai patients when compared with healthy controls [33].
The study in Thailand has also identified an extended HLA
class I, II, III (TNF, LTA) haplotype in secondary DHF
patients, correlating with in vivo intracellular cytokine
production in the acute viraemic phase of infection [33].
c. Integrated comprehension of the MHC associations
Regarding disease severity association, some differ-
ences were observed in HLA allele frequency when com-
paring DHF/DSS and DF, including A*0203, B*52 [25] and
DRB1*04 [26] as protective factors; while B*51 [25],
DQB1*0302 [35] and TNF-α- LTA haplotype [33] were
noted as susceptible factors in Thai and Mexican studies.
These findings suggest that DF and DHF arise from distinct
immune response processes.
It has been thirty years since the first report on HLA
association to dengue infection [36]. Many associations
have been cited in the interim, but none has been replicated
except for susceptible HLA- A*24 alleles in Vietnamese
[7, 32]. Moreover, the latter finding was reproduced in two
different study sites in Vietnam. A study in Malaysia also
found a DHF risk trend (2 fold) of A*24 in a Chinese group
[37]. Further subtyping, A*2402/03/10 with histidine at
codon 70, elicited a stronger significant association in the
Vietnamese but not in the Malaysian population, although
the latter involved a much smaller sample size. The HLA
class II associations in the Kinh population, however, were
not consistent with the above findings [7, 32].75 N.T.P. Lan et al.
Table 1. Association of classical class I and II HLA polymorphism and dengue
Note: DF: dengue fever, DHF: dengue hemorrhagic fever, DSS: dengue shock syndrome. 1st: Primary infection, 2nd: Secondary
infection.
DV: dengue virus (serotype). OR: Odds ratio, 95% CI: 95% confidence intervals, Pc: corrected p, ns: non significant, Author data:
*0.08 ; **0.01–0.76
A. Cases vs. healthy controls
HLA Allele Infection Serotype Case (n) Control OR 95% CI P value Pc value Population Reference
Susceptible
A*0203 2nd DV-1 DF (49) 140 2.65 1.14–46.12 0.02 ns Thai 25
A*0203 2nd DV-3 DF (26) 140 3.4 1.61–12.03 <0.0005 0.012 Thai 25
A*0203 2nd all DF (106) 140 3.09 1.59–6.02 <0.0005 0.012 Thai 25
B*52 2nd DV-2 DF (17) 140 24.91 4.61–150.14 <0.0001 <0.0001 Thai 25
B*52 2nd – DF (106) 140 5.83 1.48–26.80 0.0067 0.027 Thai 25
DQB1*01 – – DF (23) 34 3.12 0.09–10.9 0.04 ns Mexican 35
DQB1*0202 – – DF (23) 34 7.00 1.11–73.8 0.012 ns Mexican 35
DQ1 – – DF (64) 201 2.4 2.4 <0.01 0.021 Brazilian 55
A*24, codon 70 histidine – – DHF (59) 200 2.02 1.01–3.95 0.038 – Vietnamese, VL 04-05 7
A*24, codon 70 histidine – – DHF (117) 250 1.75 1.02–2.98 0.033 – Vietnamese, HCMC 7
A*0207 2nd DV-1 DHF/DSS (32) 140 2.73 1.03–7.18 0.043 ns Thai 25
A*0207 2nd DV-2 DHF/DSS (36) 140 2.64 1.03–6.70 0.041 ns Thai 25
A*0207 2nd DV-1, DV-2 DHF/DSS (103) 140 2.68 1.26–5.72 0.0084 ns Thai 25
A*0207 2nd All DHF/DSS (103) 140 2.35 1.19–4.68 0.012 ns Thai 25
A*03 – – DHF/DSS (51) 95 5.23 1.19–23.02 0.015 ns Malay, Chinese, Indian 37
B*13 – – DHF/DSS (19) 95 – – 0.049 ns Malay 37
B*51 2nd All DHF/DSS (103) 140 4.11 1.44–12.28 0.0052 0.021 Thai 25
B*51 2nd DV-1 DHF/DSS (32) 140 4.14 1.0–16.85 0.049 ns Thai 25
B*53 – – DHF/DSS (51) 95 – – 0.042 ns Malay, Chinese, Indian 37
A*24 – – DHF/DSS (309) 251 1.54 1.05–2.25 0.021 – Vietnamese 32
A*02 2nd – DSS (41) 138 – – 0.047 – Thai 36
A*24, codon 70 histidine – – DSS (152) 250 1.89 1.16–3.09 0.008 – Vietnamese, HCM 7
A*24, codon 70 histidine – – DSS (170) 200 1.7 1.04–2.79 0.03 – Vietnamese, VL 02-03 7
A*24, codon 70 histidine – – DSS (96) 200 2.09 1.18–3.70 0.0075 – Vietnamese, VL 04-05 7
B blank 2nd – DSS (41) 138 – – <0.02 – Thai 36
A*31 – DV-2 DF, DHF/DSS (120) 189 7.6 2.3–27.7 <0.0001 0.0002 Cuban 27
B*15 – DV-2 DF, DHF/DSS (120) 189 4.46 1.96–10.29 <0.0001 0.0002 Cuban 27
B*51 2nd DV-3 DF, DHF/DSS (51) 140 4.16 1.22–14.45 0.018 ns Thai 25
Resistant
DRB1*11 – – DF (47) 34 0.09 0–0.64 0.003 0.03 Mexican 26
DQB1*0302 – – DF (23) 34 0.23 0.06–0.84 0.011 ns Mexican 35
DRB1*0901 1st – DHF (59) 200 0.22 0.02–0.95 0.027 0.3 Vietnamese, VL 04-05 7
A*33 – – DHF/DSS (309) 251 0.56 0.34–0.93 0.014 – Vietnamese 32
B*18 – – DHF/DSS (51) 95 – – 0.017 ns Malay, (Chinese, Indian) 37
B*13 2nd – DSS (41) 138 – – – – Thai 36
DRB1*0901 – – DSS (170) 200 0.56 0.34–0.93 0.018 0.2 Vietnamese, VL 02-03 7
DRB1*0901 – – DSS (96) 200 0.37 0.18–0.72 0.0018 0.02 Vietnamese, VL 04-05 7
B*35 – – DF, DHF/DSS (39) 34 0.12 0.037–0.39 <0.0001 0.01 Mexican 35
DRB1*04 2nd DV-2 DF, DHF/DSS (77) 189 0.19 0.05–0.63 0.001 0.01 Cuban 27
DRB1*07 – DV-2 DF, DHF/DSS (120) 189 0.25 0.11–0.55 0.0001 0.0004 Cuban 27
B. DHF/DSS vs. DF
HLA Allele Infection Serotype DHF/DSS DF OR 95% CI P value Pc value Population Reference
Susceptible
B*48 2nd – 132 169 – – <0.001 <0.035 Thai 33
B*51 2nd – 103 106 3.07 1.07–9.22 0.036 ns Thai 25
DQB1*0302 – – 16 23 5.02 1.05–25.34 0.018 ns Mexican 35
Resistant
A*0203 2nd – 103 106 0.41 0.2–0.82 0.01 ns Thai 25
B*52 2nd – 103 106 0.08 0.00–0.59 0.049 0.02 Thai 25
DRB1*04 – – 34 47 0.31 0.11–0.85 0.011 ns Mexican 26
C. Class III
HLA Allele Infection Serotype Cases Controls OR 95% CI P value Pc value Population Reference
TNF-α (-308 -238 +488) 
GAG 2nd – DHF/DSS (132) NC (143) 2.38 1.01–5.7 0.03 ns Thai 33
TNF-α-308 A – DV-1/DV-2 DSS (43) NC (99) 3.51 1.77–7.00 0.00006 0.0001 Cuban 23
TNF-α-308AG – DV-1/DV-2 DSS (43) NC (99) 4.07 1.45–11.43 0.005 0.013 Cuban 23
TNF-α (-308/-238/+488) 
GGA 1st – DHF/DSS (10) DF (59) 12.2 * 1.73–86.1** 0.019 ns Thai 33
TNF-α (-308/-238/+488) 
GAG 2nd – DHF/DSS (132) DF (169) 4.13 1.59–11.17 < 0.001 0.022 Thai 33
TNF-1,4 LTA-1,3 &TNF-
1,4 LTA-3,3 2nd – DHF/DSS (129) DF (163) – – <0.001 0.014 Thai 33
TNF-238A &LTA 
(+249/+365/+720) AGC – – DHF (129) DF (163) 4 1.4–11.7 0.003 0.034 Thai 33
TNF-α (-308 -238 +488) 
GGA 1st – DF (59) NC (143) 0.24 0.04–1.15 0.046 ns Thai 33
TNF-α-308 GG – DV-1/DV-2 DSS (43) NC (99) 0.35 0.16–0.75 0.007 0.001 Cuban 2376 Tropical Medicine and Health Vol.39 No.4 Supplement, 2011
2.2 Non MHC genes
Studies on the association between susceptibility to DI
and polymorphic non-HLA gene have increased recently
(Table 2).
a. Fcγ receptor II (FcγRII, CD32)
FcγR is a widely distributed receptor for IgG sub-
classes and can mediate ADE in DI [38]. Homozygotes for
the arginine variant at position 131 (R/R131) of the FcγRII
gene were shown to be protective against DSS in a Viet-
namese population [39], and also against DHF/DSS in a
Cuban population with asymptomatic control [22]. This is
the first consistent finding of host genetic analysis in DI
between two very different ethnic groups from Southeast
Asia and South America.
b. Vitamin D receptor (VDR)
VDR, an immune mediator expressed on monocytes,
activated B and T cells. VDR polymorphism (rs731236 T/C)
analysis in a Vietnam study has shown that C allele (author
named as t allele) at position 352 was resistant to DSS
(p trend analysis) [39]. This correlates with a recent report
that VDR T allele was a risk factor of type 2 diabetes with
insulin secretion capacity [40].
Table 2. Non-HLA polymorphism and dengue
Note: DF: dengue fever, DHF: dengue hemorrhagic fever, DSS: dengue shock syndrome. 1st: Primary infection, 2nd: Secondary
infection. DV: dengue virus (serotype). OR: Odds ratio, 95%CI: 95% confidence intervals, Pc: corrected p, ns: non-significant
A. Cases vs. healthy controls
Factors Infect Serotype Case Control OR 95% CI p pc Population Reference
Susceptible
IL-10 (-1082/-819/-592) 
ACC/ATA – DV-1/DV-2 DSS (43) NC (99) 2.54 1.12–5.73 0.02 0.03 Cuban 23
TNFα -308A & INFγ 
874T – DV-1/DV-2 DSS (43) NC (99) 3,968 1.48–10.62 0.004 0.009 Cuban 23
TNFα -308A & IL-10 
(-1082/-819/-592) 
ACC/ATA
– DV-1/DV-2 DSS (43) NC (99) 10,057 2.03–49.72 0.001 0.003 Cuban 23
TNFα -308A & IL-10 
(-1082/-819/-592) 
ACC or ATA
– DV-1/DV-2 DSS (43) NC (99) 3,924 1.78–8.64 0.0004 0.001 Cuban 23
IFN-γ & IL10 
(-1082/-819/-592) 
ACC/ATA
– DV-1/DV-2 DSS (43) NC (99) 17,306 2.05–145.73 0.001 0.002 Cuban 23
TNFα-308A & TGF1 
codon 25C – DV-1/DV-2 DSS (43) NC (99) 5,333 1.50–18.89 0.005 0.013 Cuban 23
TNFα-308A & INFγ + 
874T & IL10 
(-1082/-819/-592) ATA
– DV-1/DV-2 DSS (43) NC (99) 9,162 1.81–46.31 0.002 0.006 Cuban 23
DC-SIGN1-336G – – DHF/DSS (454) NC (696) 0.204 – 2×10
−6 – Thai (3 cohorts) 41
TAP1 333 Val & HPA 1b – – DHF/DSS (107) NC (100) – – <0.05 – South Indian 42
TNF-308 AA or AG & 
IL-10-1082 AA – – DHF (25) NC (46) 19.47 1–378.2 0.013 ns Venezuelan 31
TAP1 333 Ile/Val – – DHF (75) NC (100) 2.7 1.46–5.01 0.005 – South Indian 42
FcγRIIa H/H131 – DV-4 DF (68) SI (42) 4,425 1.10–20.52 0.016 – Cuban 22
HPA1 1a/1b – – DSS (32) DHF (75) 4.75 – 0.003 – South Indian 42
FcγRIIa H/H131 – DV-4 DSS (29) SI (42) 10.56 2.33–54.64 0.00018 – Cuban 22
TNF-308 AA or AG & 
IL-10-1082 AA – – DHF (25) DF (41) 17.4 0.89–338 0.017 ns Venezuelan 31
Resistant
Vitamin D receptor 352 C – – DSS (352) NC (251) – – 0.033 – Vietnamese 32
TGFβ1 codon25 G allele – DV-1/DV-2 DSS (43) NC (99) 0.38 0.21–0.69 – 0.002 Cuban 23
TGFβ1 codon25 GG – DV-1/DV-2 DSS (43) NC (99) 0.34 0.15–0.76 – 0.01 Cuban 23
TNFα-308G & INFγ + 
874A & TGFβ1 codon25 
GG
– DV-1/DV-2 DSS (43) NC (99) 0.291 0.09-0.89 0.025 0.044 Cuban 23
B. DHF/DSS vs. DF
Factors Infect Serotype Case Control OR 95% CI p pc Population Reference
Susceptible
TAP1 333 Ile/Val – – DHF (75) DF (91) 2.58 – 0.007 – South Indian 42
HPA 1a/1a – – DHF (75) DF (91) 1.93 – 0.006 – South Indian 42
HPA 2a/2b – – DHF (75) DF (91) 2.8 – 0.007 – South Indian 42
TGFβ1-509 CC – DV-2 DHF (100) DF (150) 1.94 1.04-3.61 0.034 – Taiwanese 49
CTLA-4 +49 G & 
TGFβ1-509 CC – – DHF (100) DF (150) 2.10 1.07–4.09 0.028 – Taiwanese 49
JAK1 rs11208534 (TT) – – DHF (50) DF/ SI 5.19 2.13–12.66 <0.05 – Brazilian 24
Resistant
DC-SIGN1-336G – – DHF/DSS (454) DF (152) 5.84 2.77–12.31 1.4×10
−7 – Thai (3 cohorts) 41
TNF-308 GG & IL10-
1082 AA – – DHF (25) DF (41) 0.275 0.094–0.805 0.023 ns Venezuelan 31
JAK1 rs310196 (TT) – – DHF (50) DF/ SI 0.3 0.15–0.57 <0.05 – Brazilian 2477 N.T.P. Lan et al.
c. Dendritic Cell-Specific ICAM-3 Grabbing Nonintegrin
(DC-SIGN, CD209)
DC-SIGN is an essential attachment molecule for
dengue virus, expressed on the surface of DCs. The fact that
DC-SIGN variant (rs4804803) protects for the supposition
against DF but not DHF/DSS in three cohorts in Thailand
[41] provided further evidence that DHF/DSS is caused
by a different pathogenic mechanism than DF. This study
found a decreased transcription activity of G allele versus A
allele of DC- SIGN1–336, suggesting a protective effect of
G allele against DF by decreased levels of the viral receptor
expression of host cells. The subsequent analysis of this
SNP in Brazilian population, however, did not show any
association [24].
d. Transporter associated with Antigen Processing (TAP)
TAP is a protein that specializes in delivering cytosolic
peptides to class I molecules in the endoplasmic reticulum.
TAP gene variants have shown their effect on the outcome
of HPV, hepatitis C infections and autoimmune disorders
[42]. A TAP1 polymorphism (rs1057141) study in South
India showed that a heterozygous at 333 position (Ile/Val)
was susceptible to DHF [42].
e. Human Platelet Antigen (HPA)
HPA facilitates the interaction between platelets and
endovascular wall components. HPA-1a and 1b are the
33Leu substitution for 33Pro in the b3 component of allbb3
complex. The Indian study found that HPA polymorphism
associated with the severity of DI, especially heterozygous
HPA 1a/1b, increases the risk of developing DSS rather
than DHF [42]. These authors proposed that the positive
correlation of TAP1 333 and HPA1 in DHF could contribute
to the role of TAP in viral peptide selection and cross-
reactive immune response against HPA1 antigen.
f. Cytokine polymorphisms and dengue
Cytokine storm after T cell activation has been cited as
a cause of plasma leakage [43]. The production of cytokines
is modulated by genetic polymorphisms that are associated
with susceptibility to disease [31]. Interleukin (IL)-10, IL-6,
Transforming Growth Factor b-1 (TGFβ1), TNF-α, and
IFN-γ polymorphisms that may play a role in enhancing
severe dengue disease [15] were selected for the study.
IL-10 is a major immunomodulation mediator produced
by monocyte, DCs, and T, B lymphocytes, and it is an
important anti-inflammatory cytokine [44]. IL-10-1082
genotyping did not show any association with dengue in a
Venezuelan study [31], but IL-10 (-1082/-819/-592) ACC/
ATA haplotype was significantly associated with DHF in
a Cuban study (OR = 2.54, Pc = 0.03) [23]. Since Il-10
was involved with TNF-α in the thrombocytopenia and
hemorrhagic manifestation in dengue infection, the combi-
nation of TNF-α and IL-10 polymorphism is of interest.
TNF-α-308 AA or AG and IL-10-1082 AA genotype (High
TNF/low IL-10 phenotype) was more frequent in DHF
patients as compared with controls (OR = 19.47) or DF
(OR = 17.4); by contrast, the combination of TNF-α-308
GG and IL-10-1082 AA genotype (Low TNF/low IL-10
phenotype) was less frequent in DHF than in DF (OR =
0.275) [31]. Many combinations of TNF-α, IFN-γ, TGFβ1
polymorphisms and IL-10 haplotype were found to be
associated with DHF as compared with controls by Perez
2010, as shown in Table 2.
Transforming Growth Factor β-1 (TGFβ1) is a multi-
functional cytokine. Chen RF et al. (2009) showed that
individual carried TGFβ1-509 CC genotype was about
twice more likely to have DHF than DF in Taiwanese.
Moreover, its combination with CTLA-4 +49 G allele
increased the risk of DHF and had higher DV-2 virus load
than in patients with CTLA-4 +49 G allele - TGFβ1-509 T
allele (p = 0.013). This finding indicated a relationship
among immune gene, viral load and disease severity.
Conversely, Perez et al. (2010) analyzed TGFβ1 at codon
25 and noted the protective effect of G allele and GG
genotype against DHF.
2.3 Genome-wide study
The results of candidate gene studies show that the
sequencing data of the human genome and the HapMap
project have identified millions of SNPs facilitating the
implementation of GWASs.
Illumina microbead array technology was used to
genotype 728 SNPs in 56 key genes of the Type I TNF
response pathway and other well selected genes in a
Brazilian study [24]. There were 58 markers with p < 0.05,
among which 11 markers are in Janus-Activated Kinase
gene (JAK1), representing the largest proportion of signifi-
cant markers. The most significant SNPs as well as DHF
risk SNPs (rs11208534, rs2780831, rs310196) were located
toward the 5’ end of the JAK1 gene. Linkage disequilibrium
(LD) analysis showed that the SNPs rs11208534 and
rs2780831 were located in the same linkage block and that
rs310196 was an independent marker (D' rs2780831/
rs11208534 = 1, rs2780831/rs310196 = 0.924, rs11208534/
rs310196 = 0.856). JAK1 is a signaling protein associated
with the type IFN receptor, and polymorphism in this gene
may provoke the under-expression observed in severe
dengue as in the expression profile of DSS patients vs. DF
[45].
The technological development of high throughput
genotyping has provided a powerful tool to examine the
genetic basis of disease through GWAS. The GWAS
approach, underway since 2007, has achieved success in
identifying genes for many diseases like Crohn’s disease,78 Tropical Medicine and Health Vol.39 No.4 Supplement, 2011
rheumatoid arthritis, type 1 and type 2 diabetes, prostate
cancer macular degeneration [2], but little information on
large scale SNP analysis of infectious diseases, including
dengue, is available. With the large number of markers
typed, the stringent statistical criteria necessary to minimize
false positive results may be difficult to establish.
2.4 Transcript analysis
Understanding the pathogenesis of a complicated
disease like dengue remains elusive because of the lack of a
suitable animal model and the complex immune interac-
tions in infected subjects. Gene expression studies provided
an opportunity to observe the simultaneous biological
relevance and interaction of genes in the disease [46].
The expression of mRNA transcripts and protein
products of selected immune response genes has been
measured in the plasma of DF and DHF patients during the
acute and convalescent phases of DENV infection. High
levels of soluble IL-2 receptor, IL-13, IL-18, IL-10, soluble
VCAM-1, soluble CD8, macrophage inhibitory factor and
TNF all correlate with disease severity in dengue and indi-
cate a high degree of T cell activation [11, 30, 47, 48, 49].
2.5 Genome expression
The development of genomics technology, microarray
and high throughput quantitative PCR have revolutionized
the way we study gene expression modification on a large
scale and look for each change that could be important in
the pathogenic process. Information from this high-
throughput screening of whole transcriptomes requires
careful confirmation at the phenotype level.
Host gene expression was deciphered in cells infected
with DENV in vitro [50, 51] and subsequently in patients
[45, 51, 52, 53, 54] (Table 3). These studies mainly tried to
distinguish the DSS from DF or DHF grades I/II patients
(uncomplicated dengue) by comparing whole blood tran-
scription profiles of the acute stage with those of the
convalescent stage, and the healthy controls. Despite the
limited sample number, the studies revealed many upregu-
lated genes, and the host response pathways during dengue
infection were elucidated by the functional studies that
ensured. Gene expression profile in the early samples
suggested that the innate immune response, endoplasmic
reticulum (ER) stress response, cellular mitotic activity, B
cell activation, innate immune response, apoptosis and
oxygen transport, and ubiquitin proteasome dominated in
DV- infection [45, 51].The most important findings were
the less abundant transcriptions among DSS-gene signature
than in those with less-severe dengue at the time of cardio-
vascular decompensation of both innate and acquired
immune responses including T, NK cell response [52, 53],
IFN-stimulated genes (ISGs) [45], and type I IFN pathway
[9, 45, 51].
Considering that early host responses may reflect
components of the disease pathogenesis, Tolfvenstam et al.
preferred to focus on disease timing rather than disease
severity by comparing dengue infection vs. non-dengue
infection groups. They observed a strong activation of the
Table 3. Genome expression of dengue infection
Note: DF: dengue fever, DHF: dengue hemorrhagic fever, DSS: dengue shock syndrome, DI: dengue infection, 2nd: Secondary infec-
tion, ER: endoplasmic reticulum, ISGs: IFN-stimulated genes, NA: not applicable
Population Subjects Sampling time Genes (abundant) expression 
associated with DI Gene expression associated with DSS Reference
1 Vietnamese adults 6 DSS: 8 non-DSS: 
4 control (2nd)
- Admission 
- A month later
The ER stress response, cellular mitotic 
activity, B cell activation, innate 
immune response, apoptosis & oxygen 
transport.
Increased B cell activation. Decreased 
ISGs, IFN-regulated, immune response.
45
2 Singapore adults 10 DF: 10 non-dengue - before day3 
- day 7 
- 3–4 weeks later
NF-KB (IP-10), type I IFN (I-TAC) 
and ubiquitin proteasome.
NA 51
3 Thai children 1 DSS: 3 DHF : 5 DF - Admission 
- A month later
Metabolic and signal transduction, 
IFN-inducible and IFN-induced genes.
Decreased both innate & acquired 
immune responses: cytokine/chemokine 
signaling molecule production, T and B 
cell activation, & killer cell activation.
52
4 Vietnamese (adult?) 9 DSS: 9 non-DSS - Day 4 
- A month later
Oxidative metabolism, interferon 
signaling, protein ubiquitination, 
apoptosis, and cytokines.
Decreased apoptotic and type I IFN 
pathways.
9
5 Cambodian children 19 DSS: 13 DHF: 
16 DF
–– Decreased T, NK lymphocyte responses, 
increased anti-inflammatory, repair/
remodeling transcripts, innate immunity, 
inflammation and lipid metabolism.
53
6 Singapore adults 31 DI: 26 non- den - before day3 
- day 4–7 
- 3–4 weeks later
Innate immune response: IFN-signal-
ing, pathogen recognition, and comple-
ment activation, biosynthesis, metabo-
lism. Decreased T cell associated path-
ways.
NA 5479 N.T.P. Lan et al.
innate immune response (chemokines CCL2 (MCP-1),
CCL8 (MCP-2), CXCL10, (IP-10) and CCL3 (MIP-1α)) in
the early dengue fever phase (before 72 h of fever), while
the adaptive immune response, biosynthesis and metabolism
dominated in the defervescence phase (day 4–7 of fever).
Again, the expression profiles are so variable that it
may be difficult to reach a consensus and may even cause
controversy. Some authors have highlighted the importance
of timing in the course of dengue disease and suggested that
the change in DSS transcription profile may occur earlier
than clinical manifestations [9]. Devignot et al. concluded
that a shift from DSS to uncomplicated transcriptional
profile may occur within a very short time by showing that
DSS samples at three days after shock exhibited a profile
very close to uncomplicated dengue [53].
3. CONCLUSION
Taken together, these studies reveal that associations
between host genetics, DV, and clinical outcome are
complex. The question of how many genes contributes to
dengue susceptibility, how they interact to cause severe
manifestations, and the extent to which the pathogenesis
mechanism might be genetically predicted remains unknown.
It is still a challenge to identify appropriate epitopes for
vaccines, and further exploration is needed to identify
specific medicine candidates.
Many essential issues will exert an impact on future
study design, including uniform case definition, adequate
sample size, quality control in typing technique, and
statistical analysis method with locus-wise correction of p
value. The associations should also be verified subsequently
by well-designed functional studies.
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